Drug Search Results
More Filters [+]

MKC-253

Alternative Names: mkc-253, mkc253, mkc 253
Latest Update: 2023-03-17
Latest Update Note: PubMed Publication

Product Description

For Diabetes Mellitus, Type 2 (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00475371)

Mechanisms of Action: GLP-1 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mannkind
Company Location: WESTLAKE VILLAGE CA 91362
Company CEO: Michael E. Castagna
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MKC-253

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MKC-253-002

P1

Completed

Type 2 Diabetes

2008-09-01

2007-003430-42

P2

Completed

Type 2 Diabetes

2008-06-10

MKC-253-001

P1

Completed

Type 2 Diabetes

2007-06-01

Recent News Events